Erratum: CDK6 as a key regulator of hematopoietic and leukemic stem cell activation (Blood (2015) 125 1 (90-101) DOI: 10.1182/blood-2014-06-584417);CDK6 as a key regulator of hematopoietic and leukemic stem cell activation

Blood

Volumn 125, Issue 1, 2015, Pages 90-101

  Scheicher, Ruth ^a   Hoelbl Kovacic, Andrea ^a   Bellutti, Florian ^a   Tigan, Anca Sarmiza ^a   Prchal Murphy, Michaela ^a   Heller, Gerwin ^b   Schneckenleithner, Christine ^a   Salazar Roa, María ^c   Zöchbauer Müller, Sabine ^b   Zuber, Johannes ^d   Malumbres, Marcos ^c   Kollmann, Karoline ^a,e   Sexl, Veronika ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 6; EARLY GROWTH RESPONSE FACTOR 1; FLUOROURACIL; BCR ABL PROTEIN; CDK6 PROTEIN, MOUSE; EGR1 PROTEIN, MOUSE; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL ACTIVATION; CELL CYCLE; CONTROLLED STUDY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; LEUKEMIC STEM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; STEADY STATE; ANIMAL; C57BL MOUSE; CELL TRANSPLANTATION; CYTOLOGY; DISEASE COURSE; GENETIC TRANSCRIPTION; GENETICS; LEUKEMIA; METABOLISM; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; SCID MOUSE; STEM CELL; TRANSGENIC MOUSE;

ANIMALS; CELL CYCLE; CELL TRANSPLANTATION; CYCLIN-DEPENDENT KINASE 6; DISEASE PROGRESSION; EARLY GROWTH RESPONSE PROTEIN 1; FUSION PROTEINS, BCR-ABL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; LEUKEMIA; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; POLY I-C; STEM CELLS; TRANSCRIPTION, GENETIC;

EID: 84920591660     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2018-07-863001     Document Type: Erratum

References (53)

1. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18(22):2699-2711.
2. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002;2(12):910-917.
3. Kozar K, Sicinski P. Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes. Cell Cycle. 2005;4(3):388-391.
4. Malumbres M, Sotillo R, Santamaría D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004; 118(4):493-504.
5. Hu MG, Deshpande A, Enos M, et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 2009;69(3):810-818.
6. Fujimoto T, Anderson K, Jacobsen SEW, Nishikawa S-I, Nerlov C. Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction. EMBO J. 2007;26(9):2361-2370.
7. Kollmann K, Heller G, Schneckenleithner C, et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013;24(2):167-181.
8. Handschick K, Beuerlein K, Jurida L, et al. Cyclin-dependent kinase 6 is a chromatin-bound cofactor for NF-κB-dependent gene expression. Mol Cell. 2014;53(2):193-208.
9. van der Linden MH, Willekes M, van Roon E, et al. MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. Cell Cycle. 2014;13(5):834-844.
10. Placke T, Faber K, Nonami A, et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014;124(1):13-23.
11. Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 2008;132(4): 631-644.
12. Wilson A, Laurenti E, Oser G, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135(6):1118-1129.
13. Min IM, Pietramaggiori G, Kim FS, Passegué E, Stevenson KE, Wagers AJ. The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell. 2008;2(4):380-391.
14. Ichikawa M, Goyama S, Asai T, et al. AML1/Runx1 negatively regulates quiescent hematopoietic stem cells in adult hematopoiesis. J Immunol. 2008;180(7):4402-4408.
15. Lacombe J, Herblot S, Rojas-Sutterlin S, et al. Scl regulates the quiescence and the long-term competence of hematopoietic stem cells. Blood. 2010;115(4):792-803.
16. Wilson A, Laurenti E, Trumpp A. Balancing dormant and self-renewing hematopoietic stem cells. Curr Opin Genet Dev. 2009;19(5):461-468.
17. Wang JCY, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005;15(9): 494-501.
18. Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol. 2010;10(3):201-209.
19. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003;423(6937):255-260.
20. Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12(6): 528-541.
21. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009; 458(7239):776-779.
22. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834-846.
23. Rodríguez-Díez E, Quereda V, Bellutti F, et al. Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis. Blood. 2014;124(15): 2380-2390.
24. Bauer S, Grossmann S, Vingron M, Robinson PN. Ontologizer 2.0-a multifunctional tool for GO term enrichment analysis and data exploration. Bioinformatics. 2008;24(14):1650-1651.
25. Sandelin A, Alkema W, Engström P, Wasserman WW, Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2004; 32(Database issue):D91-D94.
26. Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q. GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol. 2008; 9(Suppl 1):S4.
27. Streit M, Lex A, Kalkusch M, Zatloukal K, Schmalstieg D. Caleydo: connecting pathways and gene expression. Bioinformatics. 2009; 25(20):2760-2761.
28. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121(7):1109-1121.
29. Lerner C, Harrison DE. 5-Fluorouracil spares hemopoietic stem cells responsible for long-term repopulation. Exp Hematol. 1990;18(2):114-118.
30. van der Wath RC, Wilson A, Laurenti E, Trumpp A, Liò P. Estimating dormant and active hematopoietic stem cell kinetics through extensive modeling of bromodeoxyuridine labelretaining cell dynamics. PLoS ONE. 2009;4(9): e6972.
31. Essers MAG, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904-908.
32. Maillard I, Koch U, Dumortier A, et al. Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. Cell Stem Cell. 2008;2(4):356-366.
33. Li D, Ilnytskyy Y, Kovalchuk A, et al. Crucial role for early growth response-1 in the transcriptional regulation of miR-20b in breast cancer. Oncotarget. 2013;4(9):1373-1387.
34. Myung E, Park Y-L, Kim N, et al. Expression of early growth response-1 in human gastric cancer and its relationship with tumor cell behaviors and prognosis. Pathol Res Pract. 2013;209(11): 692-699.
35. Myung D-S, Park Y-L, Kim N, et al. Expression of early growth response-1 in colorectal cancer and its relation to tumor cell proliferation and apoptosis. Oncol Rep. 2014;31(2):788-794.
36. Lai J-K, Wu H-C, Shen Y-C, Hsieh HY, Yang SY, Chang CC. Krüppel-like factor 4 is involved in cell scattering induced by hepatocyte growth factor. J Cell Sci. 2012;125(Pt 20):4853-4864.
37. Kovacic B, Hoelbl A, Litos G, et al. Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Mol Med. 2012;4(4):283-297.
38. Hu MG, Deshpande A, Schlichting N, et al. CDK6 kinase activity is required for thymocyte development. Blood. 2011;117(23):6120-6131.
39. Sirin O, Lukov GL, Mao R, Conneely OM, Goodell MA. The orphan nuclear receptor Nurr1 restricts the proliferation of haematopoietic stem cells. Nat Cell Biol. 2010;12(12):1213-1219.
40. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol. 2002;193(3):287-292.
41. Laslo P, Spooner CJ, Warmflash A, et al. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell. 2006;126(4):755-766.
42. Boone DN, Qi Y, Li Z, Hann SR. Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism. Proc Natl Acad Sci USA. 2011; 108(2):632-637.
43. Huang RP, Fan Y, de Belle I, et al. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer. 1997;72(1):102-109.
44. Calogero A, Arcella A, De Gregorio G, et al. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Clin Cancer Res. 2001; 7(9):2788-2796.
45. Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am. 1996; 10(2):293-320.
46. Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007;110(2):719-726.
47. Stoddart A, Fernald AA, Wang J, et al. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood. 2014;123(7): 1069-1078.
48. Shafarenko M, Liebermann DA, Hoffman B. Egr-1 abrogates the block imparted by c-Myc on terminal M1 myeloid differentiation. Blood. 2005; 106(3):871-878.
49. Krones-Herzig A, Mittal S, Yule K, et al. Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res. 2005;65(12):5133-5143.
50. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006;13(2):115-124.
51. Essers MAG, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol. 2010;4(5):443-450.
52. Pellicano F, Sinclair A, Holyoake TL. In search of CML stem cells' deadly weakness. Curr Hematol Malig Rep. 2011;6(2):82-87.
53. Irvine DA, Heaney NB, Holyoake TL. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors-a synthesis of clinical and laboratory data. Blood Rev. 2010;24(1):1-9.